Antonella Lombardo

Prof. Dr. Antonella Lombardo


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2023 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
MMmaria chiara meucci
maria chiara meucci
SMSilvia Malara
Silvia Malara
SBSteele C Butcher
Steele C Butcher
KHKensuke Hirasawa
Kensuke Hirasawa
FKFrank van der Kley
Frank van der Kley
Francesca GrazianiFrancesca Graziani
Francesca Graziani

28 July 2022 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Open access
PDF file
MMmaria chiara meucci
maria chiara meucci
RLRosa Lilo
Rosa Lilo
ALAntonella Lombardo
Antonella Lombardo
GLGaetano Antonio Lanza
Gaetano Antonio Lanza
MBMarianne Bootsma
Marianne Bootsma
Francesca GrazianiFrancesca Graziani
Francesca Graziani
To perform a comparative analysis of right ventricle (RV) myocardial mechanics, assessed by 2D speckle-tracking echocardiography (2D-STE), between patients with Fabry disease and patients with sarcomeric disease. Patients with Fabry cardiomyopathy (FC) (n = 28) were compared with patients with sarcomeric hypertrophic cardiomyopathy (HCM), matched for degree of left ventricle hypertrophy (LVH) and demographic characteristics (n = 112). In addition, patients with Fabry disease and no LVH [phenotype-negative carriers of pathogenic α-galactosidase gene mutations (GLA LVH-)] (n = 28) were compared with age and sex-matched carriers of sarcomeric gene mutations without LVH [Phenotype-negative carriers of pathogenic sarcomeric gene mutations (Sarc LVH-)] (n = 56). Standard echocardiography and 2D-STE were performed in all participants. Despite a subtle impairment of RV global longitudinal strain (RV-GLS) was common in both groups, patients with FC showed a more prominent reduction of RV free wall longitudinal strain (RV-FWS) and lower values of difference between RV-FWS and RV-GLS (ΔRV strain), in comparison to individuals with HCM (P < 0.001 and P = 0.002, respectively). RV-FWS and ΔRV strain demonstrated an independent and additive value in discriminating FC from HCM, over the presence of symmetric LVH, systolic anterior motion of the mitral valve and RV hypertrophy. Similar results were found in GLA LVH- patients: they had worse RV-FWS and lower values of ΔRV strain as compared to Sarc LVH- patients (both P < 0.001). Patients with FC show a specific pattern of RV myocardial mechanics, characterized by a larger impairment of RV-FWS and lower ΔRV strain in comparison to patients with HCM, which may be helpful in the differential diagnosis between these two diseases.

7 June 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
FBFrancesco Bianchini
Francesco Bianchini
Francesca GrazianiFrancesca Graziani
Francesca Graziani
CTCarlo Trani
Carlo Trani
CACristina Aurigemma
Cristina Aurigemma
PBPiergiorgio Bruno
Piergiorgio Bruno
MMMassimo Massetti
Massimo Massetti
Background: A multidisciplinary approach might be pivotal for the management of patients with valvular heart disease (VHD), but clinical outcome data are lacking. Methods and Results: At our institution, since 2014, internal guidelines recommended heart team consultations for patients with VHD. The clinical/echocardiographic characteristics, treatment recommendations, performed treatment, and early clinical outcomes of consecutive, hospitalized patients with VHD undergoing heart team evaluation were collected. Surgical risk was prospectively assessed by the EuroSCORE II and STS‐PROM. The primary end point of the study was early mortality. A total of 1004 patients with VHD with high clinical complexity (mean age, 75 years; mean EuroSCORE II, 9.4%; mean STS‐PROM, 5.6%; 48% ischemic heart disease; 29% chronic kidney disease, 9% oncologic/hematologic diseases) were enrolled. The heart team recommended an interventional treatment for 807 (80%) patients and conservative management for 197 (20%) patients. Management crossovers occurred in only 5% of patients. The recommended intervention was cardiac surgery for 230 (23%) patients, percutaneous treatment in 516 (51%) patients, and hybrid treatment in 61 (6%) patients. Early mortality occurred in 24 patients (2.4%) and was independently predicted by aortic stenosis, left ventricular ejection fraction, pulmonary artery systolic pressure, and conservative management recommendation. In patients referred to treatment, observed early mortality (1.7%) was significantly lower ( P <0.001) than expected on the bases of both the STS‐PROM (5.2%) and EuroSCORE II (9.7%). Conclusions: Within the limitations of its single‐center and observational design, the present study suggests that heart team–based management of patients with complex VHD is feasible and allows referral to a wide spectrum of interventions with promising early clinical results.

3 June 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
RLRosa Lilo
Rosa Lilo
MMmaria chiara meucci
maria chiara meucci
AFAnnamaria Del Franco
Annamaria Del Franco
EMEmanuele Monda
Emanuele Monda
GIGiulia Iannaccone
Giulia Iannaccone
Francesca GrazianiFrancesca Graziani
Francesca Graziani
Background: Fabry disease can be classified in 4 stages based on the extent of cardiac damage assessed with echocardiography. This staging is strongly associated with prognosis, with a doubled risk increase of cardiovascular events for each stage progression. The aims of the present study were to investigate the evolution of cardiac damage using this staging system during midterm follow‐up and to identify predictors of stage worsening. Methods AND RESULTS: This is a retrospective, multicenter study, which included 168 patients with Fabry disease (38% men) categorized at baseline and follow‐up in 4 stages, defined as follows: stage 0, no cardiac involvement; stage 1, left ventricular hypertrophy; stage 2, left atrial enlargement; and stage 3, ventricular impairment. After a median of 5 years, cardiac stage worsened of at least 1 class in 34 patients (24% of 143 patients in stage 0–2 at baseline), improved in 9 (12% of 73 patients in stages 1–3 at baseline), and remained stable in 125 (74% of the 168 patients enrolled). At multivariable logistic regression analysis, age (odds ratio, 1.05 [95% CI, 1.01–1.09]; P =0.006), male sex (odds ratio, 4.26 [95% CI, 1.54–11.79]; P =0.005), classic phenotype (odds ratio, 4.95 [95% CI, 1.30–18.72]; P =0.018), and renal failure (odds ratio, 10.40 [95% CI, 1.57–68.77]; P =0.015) emerged as independent predictors of cardiac damage stage deterioration. Conclusions: Fabry disease is associated with a high rate of progression of cardiac damage during midterm follow‐up, with ≈24% of patients experiencing cardiac stage worsening. Age, male sex, classic phenotype, and renal failure are independent predictors of stage progression.

21 March 2025 in European Cardiology Review
Verified
Journal Article
Open access
PDF file
Massimiliano CamilliMassimiliano Camilli
Massimiliano Camilli
LMLuca Maggio
Luca Maggio
LTLorenzo Tinti
Lorenzo Tinti
ITIlaria Torre
Ilaria Torre
MVMarcello Viscovo
Marcello Viscovo
BRBianca Rocca
Bianca Rocca
Cardio-oncology was established with the aim of defining primary and secondary prevention approaches through surveillance and the use of tools to stratify and diminish the cardiovascular risk to cancer patients. This branch of medicine also contributes to establishing a new field in translational medicine for cardiovascular disease by focusing on the interplay between cancer and heart disease. In this first article in the new cardio-oncology section of the journal, we explore the main concepts of emerging anti-cancer therapies and their plausible cardiotoxic effects and we will describe advances and gaps in knowledge, highlighting how cardio-oncology is contributing to translational cardiology. We will speculate on the complex interplay between cancer and heart failure and discuss an emerging concept known as reverse cardio-oncology. We also present the perspective that cardio-oncology represents a promising platform area of research, allowing the discovery of novel pathways involved in cardiovascular disease through the identification of toxicities induced by targeted cancer therapies.

9 November 2022 in Canadian Journal of Cardiology
Verified
Journal Article
Closed access
Massimiliano CamilliMassimiliano Camilli
Massimiliano Camilli
MVMarcello Viscovo
Marcello Viscovo
SHStefan Hohaus
Stefan Hohaus
PLPriscilla Lamendola
Priscilla Lamendola
EVElena Verrecchia
Elena Verrecchia
RMRaffaele Manna
Raffaele Manna